Jaguar Health Files 8-K: Agreements, Obligations, Equity Sales
Ticker: JAGX · Form: 8-K · Filed: 2025-06-24T00:00:00.000Z
Sentiment: neutral
Topics: material-agreement, financial-obligation, equity-sale
TL;DR
Jaguar Health dropped an 8-K: new deals, debt, and stock sales. Watch this space.
AI Summary
On June 24, 2025, Jaguar Health, Inc. filed an 8-K report detailing several significant events. These include entering into a material definitive agreement, creating a direct financial obligation, and unregistered sales of equity securities. The filing also covers other events and financial statements/exhibits.
Why It Matters
This filing indicates potential new financial commitments and equity transactions for Jaguar Health, which could impact its financial structure and shareholder value.
Risk Assessment
Risk Level: medium — The filing mentions material definitive agreements, financial obligations, and unregistered equity sales, which can introduce financial risks and dilution.
Key Players & Entities
- Jaguar Health, Inc. (company) — Registrant
- June 24, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 200 Pine Street, Suite 400 (address) — Business Address
- San Francisco, California (location) — Business Location
FAQ
What is the nature of the material definitive agreement entered into by Jaguar Health?
The filing does not specify the details of the material definitive agreement, only that one was entered into.
What type of direct financial obligation did Jaguar Health create?
The filing indicates the creation of a direct financial obligation but does not provide specific details about its nature or amount.
Were there any unregistered sales of equity securities by Jaguar Health?
Yes, the filing explicitly lists 'Unregistered Sales of Equity Securities' as an item of information.
What is the IRS Employer Identification Number for Jaguar Health, Inc.?
The IRS Employer Identification Number listed in the filing is 46-2956775.
When was Jaguar Health, Inc. formerly known as Jaguar Animal Health, Inc.?
The date of the name change from Jaguar Animal Health, Inc. to Jaguar Health, Inc. was August 30, 2013.
From the Filing
0001193125-25-145742.txt : 20250624 0001193125-25-145742.hdr.sgml : 20250624 20250624161516 ACCESSION NUMBER: 0001193125-25-145742 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20250624 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250624 DATE AS OF CHANGE: 20250624 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Jaguar Health, Inc. CENTRAL INDEX KEY: 0001585608 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36714 FILM NUMBER: 251069385 BUSINESS ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 415-371-8300 MAIL ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 FORMER COMPANY: FORMER CONFORMED NAME: Jaguar Animal Health, Inc. DATE OF NAME CHANGE: 20130830 8-K 1 d885397d8k.htm 8-K 8-K false 0001585608 0001585608 2025-06-24 2025-06-24     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025     JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter)       Delaware   001-36714   46-2956775 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)   200 Pine Street , Suite 400 San Francisco , California   94104 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code: (415) 371-8300     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, Par Value $0.0001 Per Share   JAGX   The Nasdaq Stock Market       Item 1.01 Entry into a Material Definitive Agreement Note Exchange and Warrant Purchase Agreement As previously disclosed, on March 31, 2025 Jaguar Health, Inc. (the “Company”) issued and sold to selected accredited investors (the “Original Investors”) (i) approximately $3.4 million aggregate p